BKM Wealth Management LLC Acquires 584 Shares of Zoetis Inc. (NYSE:ZTS)

BKM Wealth Management LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 7.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,393 shares of the company’s stock after acquiring an additional 584 shares during the quarter. BKM Wealth Management LLC’s holdings in Zoetis were worth $1,367,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Kestra Investment Management LLC increased its stake in Zoetis by 106.9% during the 4th quarter. Kestra Investment Management LLC now owns 6,057 shares of the company’s stock valued at $987,000 after purchasing an additional 3,129 shares in the last quarter. Venturi Wealth Management LLC increased its stake in Zoetis by 2.1% during the 4th quarter. Venturi Wealth Management LLC now owns 11,964 shares of the company’s stock valued at $1,949,000 after purchasing an additional 250 shares in the last quarter. Empower Advisory Group LLC increased its stake in Zoetis by 13.8% during the 4th quarter. Empower Advisory Group LLC now owns 1,761 shares of the company’s stock valued at $287,000 after purchasing an additional 213 shares in the last quarter. CIBC Asset Management Inc increased its stake in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its stake in Zoetis by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 106,189 shares of the company’s stock valued at $18,340,000 after purchasing an additional 918 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ZTS shares. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $214.90.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $157.54 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a market capitalization of $71.08 billion, a P/E ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90. The firm’s 50 day simple moving average is $168.51 and its two-hundred day simple moving average is $178.78.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Research analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is currently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.